en · de · es · fr · pt
tb-500-notes.peptides4962.com › Topic › Thymosin Beta-4 Fragment Background — Research Overview

Thymosin Beta-4 Fragment Background — Research Overview

By Editorial Desk · published 2026-05-12 · last reviewed 2026-06-22 · Topic

The short version of thymosin beta-4 fits in a sentence. The long version — which is the one that helps — is below.

This page was last updated on 2026-06-22 and is reviewed periodically as new material appears.

Thymosin Beta-4 Fragment Background

Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.

TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.

Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.

TB-500 Background and Identity

The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.

Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.

TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.

Tb-500 at a glance

PropertyValueNotes
Molecular classSynthetic peptideN-terminal fragment of thymosin beta-4
Residue countSevenSequence LKKTETQ
Approximate mass889 DaAcetylated seven-residue peptide
Common synonymsTB4 fragment, TB500Not identical to full-length TB4
Reported activityActin bindingObserved mainly in cell-free systems

Research Framing and Evidence Base

Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.

Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.

Related pages on this site

Handling, Storage and Quality Checks

Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.

Identity and purity checks for peptide material typically combine reversed-phase high-performance liquid chromatography with mass measurement, since retention time alone cannot confirm a sequence. Mass measurement verifies the expected molecular mass within instrument tolerance, while chromatographic peak area provides a purity estimate. Anti-doping analysis of urine uses related but more sensitive workflows, sometimes after solid-phase extraction. For research material, batch documentation, certificate content, and independent testing are common points of scrutiny, because supply chains outside pharmaceutical regulation vary widely in the paperwork they provide.

Reconstitution of a lyophilized peptide is normally done with sterile water or a suitable buffer under aseptic conditions. Adding solvent down the vial wall and allowing gentle dissolution instead of vigorous vortexing reduces the chance of aggregation, which can lower the effective concentration of the resulting solution. Concentrated stocks are usually diluted into working buffer shortly before use. Because no standard preparation protocol exists for TB-500 specifically, laboratories adapt general peptide handling practice, and reported results may reflect differing preparation choices.

Identity and Physical Form

Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.

The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.

The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.

Thymosin Beta-4 Fragment Identity

No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.

TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.

Supporting material

=== Preventing diabetes mellitus type 1 === Currently, there is no known way to prevent diabetes mellitus type 1. However, onset of diabetes mellitus type 1 may be delayed by about two years by administering Teplizumab.

They also included giving the Reserve Forces and Cadets Associations the power to produce an annual report to Parliament on the state of the volunteer reserves (the Royal Naval Reserve, The Royal Marines Reserve, the Army Reserve and the Royal Auxiliary Air Force). In January 2021, the Army Reserve trained strength stood at 26,820. (This figure excludes recruits undergoing phase 1 training and various non-deployable categories such as University Officers' Training Corps). During 2020, three reserve infantry battalions, 7 Rifles and 5 Fusiliers followed by 6 Rifles, provided the framework battalion for peacekeeping in Cyprus and over the winter 20/21 the Royal Yeomanry provided a composite squadron for a six-month tour on armoured reconnaissance as part of Britain's forward presence in Estonia. Army Reservists have a minimum commitment to serve 27 training days per year or 19 days for some national units. This period normally includes a two-week period of continuous training either as an Army Reserve unit, on courses or attached to a Regular unit. Army Reserve soldiers are paid at a similar rate to their regular equivalents while engaged on military activities.

Strict rules are identified to apply to the relationships between the Five Phases in terms of sequence, of acting on each other, of counteraction, etc. All these aspects of Five Phases theory constitute the basis of the zàng-fǔ concept, and thus have great influence regarding the TCM model of the body. Five Phase theory is also applied in diagnosis and therapy. Correspondences between the body and the universe have historically not only been seen in terms of the Five Elements, but also of the "Great Numbers" (大數; dà shū) For example, the number of acu-points has at times been seen to be 365, corresponding with the number of days in a year; and the number of main meridians–12–has been seen as corresponding with the number of rivers flowing through the ancient Chinese empire.

Valens's successor, Theodosius I (r. 379–395), secured peace in the east by allowing the Goths to settle in Roman territory; he also twice intervened in the western half, defeating the usurpers Magnus Maximus and Eugenius in 388 and 394, respectively. He actively condemned paganism, confirmed the primacy of Nicene Orthodoxy over Arianism in the East, and established Christianity as the Roman state religion. He was the last emperor to rule both the western and eastern halves of the empire. After his death, the West was destabilised but the East thrived due to the civilian administrators who continued to hold power. Theodosius II (r. 408–450) largely left the rule of the East to officials such as Anthemius, who constructed the Theodosian Walls. Constantinople had now entrenched itself as the empire's capital. Aside from Constantinople's walls, Theodosius' reign was also marked by the compilation of the Codex Theodosianus and the theological dispute over Nestorianism (a doctrine later deemed heretical). His reign also saw the arrival of Attila's Huns, who ravaged the Balkans, leading to a large tribute being exacted from the eastern empire. Attila switched his attention to the rapidly-deteriorating western empire, and his people fractured after his death in 453. Later, Leo I (r. 457–474) failed in his 468 attempt to reconquer the West. The warlord Odoacer deposed Romulus Augustulus in 476 and after the assassination of his titular successor Julius Nepos in 480, abolished the office of western emperor.

Sources: en.wikipedia.org

Notes from published material

==== Miscellaneous ==== The acute effects of LSD normally last between 6 and 12 hours depending on dose, tolerance, and age. In a modern study, the effects of the dose of LSD given lasted for up to 12 hours and were closely correlated with the concentrations of LSD present in circulation over time, with no acute tolerance observed.

Merocyanines are a class of polymethine dyes. They include quinophthalones and spiropyrans. which are clearly defined by set structural properties. Merocyanines belong to the group of dyes referred to as functional dyes, where their applications are not only determined by their colour, but also their valuable chemical properties. These dyes are usually intensely colored and have large extinction coefficients. Merocyanine 540 was the first fluorescent dye used for measuring membrane potential, while Brooker's merocyanine and related compounds are notable for their solvatochromatic properties.

A fossorial (from Latin fossor, meaning "digger") is an animal adapted to digging which lives primarily, but not solely, underground. Some examples are badgers, and naked mole-rats. Many rodent species are also considered fossorial because they live in burrows for most but not all of the day. Species that live exclusively underground are subterranean, and those with limited adaptations to a fossorial lifestyle sub-fossorial. Some organisms are fossorial to aid in temperature regulation while others use the underground habitat for protection from predators or for food storage. Fossorial mammals have a fusiform body, thickest at the shoulders and tapering off at the tail and nose. Unable to see in the dark burrows, most have degenerated eyes, but degeneration varies between species; pocket gophers, for example, are only semi-fossorial and have very small yet functional eyes, in the fully fossorial marsupial mole, the eyes are degenerated and useless, Talpa moles have vestigial eyes and the Cape golden mole has a layer of skin covering the eyes. External ears flaps are also very small or absent. Truly fossorial mammals have short, stout legs as strength is more important than speed to a burrowing mammal, but semi-fossorial mammals have cursorial legs. The front paws are broad and have strong claws to help in loosening dirt while excavating burrows, and the back paws have webbing, as well as claws, which aids in throwing loosened dirt backwards. Most have large incisors to prevent dirt from flying into their mouth.

Sources: en.wikipedia.org

Frequently asked questions

Is TB-500 the same as thymosin beta-4?

No. Thymosin beta-4 is a 43-residue protein, while TB-500 refers to a seven-residue fragment corresponding to its N-terminal region. The two names are often used loosely in commercial and community writing, which obscures the difference in size, sequence, and likely behavior.

What activity is attributed to this sequence?

The fragment contains an actin-binding motif, and cell-free experiments show that it can interact with monomeric actin. That observation is the basis for interest in cell migration and repair processes. Effects reported in animals are not established for humans.

Is there a standard purity specification?

Purity is usually stated by the supplier rather than fixed by a pharmacopoeial monograph, and typical listings report a percentage from reverse-phase HPLC. Independent verification is uncommon. Because no single accepted specification exists, comparisons between lots and between suppliers are difficult.

What is TB-500?

TB-500 is a trade-style label for a synthetic peptide connected to thymosin beta-4. It is sold mainly through research-chemical channels and is not a single chemically defined product across suppliers.

Network